Full-Time

Manager/Senior Manager

External Manufacturing

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

On-site presence (Cambridge MA) preferred 30%.

Category
Genomics
Biology Lab & Research
Biology & Biotech

You match the following Beam Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor of Science and 8+ years experience in biologics manufacturing required.
  • 3+ years experience in a management or technical MSAT position in clinical commercial manufacturing.
  • Experience developing and maintaining manufacturing operations and quality systems required.
  • Experience with managing contract manufacturing organizations required.
  • Experience in commercial manufacturing, supply chain handling, clinical manufacturing and distribution.
  • Knowledge of cGMP requirements is a must.
  • Strong leadership skills with a track record of delivering new products to clinic with external partners.
  • Strong communication skills (written and verbal), including experience presenting in front of multidisciplinary stakeholders.
Responsibilities
  • Management of CMO’s and critical suppliers; including budget planning, tracking, contracts, and manufacturing tactical execution.
  • Establish and foster strong collaborative relationships with external manufacturing partners and service providers.
  • Responsible for developing manufacturing service and supply agreements in close collaboration with Legal, Finance, Procurement, and Quality.
  • Ensure safe and compliant cGMP operations.
  • Establish and maintain detailed project plans; define risks and recommend contingency plans.
  • Align external manufacturing schedules with demand forecast requirements.
  • Ensure product delivery and supply plan is on time and within budget.
  • Resource planning, generating metrics/ KPIs, and presentation of materials for internal stakeholder review.
  • Change owner for manufacturing vendor change notifications; lead or assist with manufacturing deviations, customer complaints, and product failure investigations.
  • Travel for in-person interactions with multiple contract manufacturing entities to ensure production is on plan. 10%
  • On-site presence (Cambridge MA) preferred 30%
  • Supports the development of outsourcing models, vendor evaluation, and CMO selection in close collaboration with key internal stakeholders.
  • Perform other related duties and ad hoc projects as required by position.
Desired Qualifications
  • Cell and Gene Therapy experience preferred
  • Technical understanding of gRNA, mRNA, pDNA
  • Fill finish experience

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by emphasizing a values-driven approach, a strong team of experts, and a commitment to rigorous scientific development. Their ultimate goal is to advance genetic medicine to improve the lives of patients suffering from genetic disorders.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Base editing technology is gaining traction as a precise genetic correction method.
  • The $250 million deal with Eli Lilly boosts Beam's financial and strategic position.
  • Christi Shaw's appointment to the board brings valuable biotech leadership.

What critics are saying

  • Competition from CRISPR Therapeutics could impact Beam's market share.
  • Recent restructuring and layoffs may lead to operational challenges.
  • New CFO transition might pose financial management challenges.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise genetic correction method.
  • The company focuses on lifelong cures for genetic disorders like sickle cell disease.
  • Beam's strategic partnerships, like with Eli Lilly, enhance its market position.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
GlobeNewswire
Dec 6th, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.

CityBiz
Jul 15th, 2024
Beam Therapeutics Chief Financial Officer Terry-Ann Burrell to Retire

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.

Securities.io
May 21st, 2024
10 Rare Diseases Specialist Stocks

Rare Diseases – Curing The IncurableWhile not entirely solved, a lot of major deadly illnesses that have plagued humanity have become more manageable over the last century, from bacterial (antibiotics) and viral (vaccines) infections to diabetes (insulin).There is, however, a wide array of rare diseases which are still mostly incurable. Most of the time, this is because these diseases are not caused by an external threat, but by a biological dysfunction inside the very cells of the patient. This is quickly changing, thanks to progress in biosciences.On one hand, with the human genome sequenced and much more advanced analytical methods, scientists can finally understand what are the root causes of rare diseases. Even AI is now helping interpret the data and provide new insights .On the other hand, new technologies like gene editing open the possibility of fixing deficient cells or organs, restoring normal function.Rare diseases each affect less than 1 in 2,000 people, with more than 6000 different rare diseases. Despite their individual rarity, together, they affect around 4% of the population, with as many as 30 million people in just Europe .3/4 of rare diseases affect children, 72% are genetic in origin, and it takes on average 5 years for rare disease patients to get a diagnosis.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize .What sets CRISPR Therapeutics apart is the all-star team of founders, including Dr

Yahoo Finance
Feb 14th, 2024
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

Beam Therapeutics is developing BEAM-101 for the SCD indication in early-stage studies.

Beam
Dec 14th, 2023
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Beam Therapeutics appoints biotech executive Christi Shaw to its board of directors.